Not only is IL‐17 involved in alcoholic fatty liver disease, but has also been demonstrated to promote nonalcoholic fatty liver and nonalcoholic steatohepatitis, thus indicating that IL‐17 may contribute to MAFLD progression (Harley et al., 2014). The gene discussed is IL17A; the disease is metabolic dysfunction-associated steatohepatitis.